openPR Logo
Press release

Naproxen Market: Latest Innovations, Drivers, Restraints, Challenges and Forecast 2016 - 2024

08-07-2017 12:37 PM CET | Health & Medicine

Press release from: TMR - Research Reports

Naproxen Market: Latest Innovations, Drivers, Restraints,

Naproxen is a non-steroidal anti-inflammatory drug (NSAID) commonly used as a prescription drug as well as over-the-counter (OTC). It is generally used in low to moderate pain management and sometimes used for fever reduction. Naproxen was approved in 1976 in the U.S., and was developed originally by Syntex, then acquired by Roche and approved in the U.S. under the brand name Aleve (naproxen sodium) in 1994 for over-the-counter (OTC) use. Naproxen was approved for over-the-counter (OTC) administration due to well-established profiling of its risks/benefits for over 18 years.

Obtain Report Details: http://www.transparencymarketresearch.com/naproxen-market.html

Naproxen is available as base naproxen and salt form i.e., naproxen sodium. Both the naproxen forms are available as either tablets or liquid suspension in extended-release formulation which comes in combination with proton pump inhibitor or enteric coating to prevent from abdominal risks. Naproxen belongs to heterogeneous set of compounds known to be non-steroidal anti-inflammatory drug (NSAID), which are used as analgesics, anti-inflammatory, and anti-pyretic. Naproxen is a propionic acid derivative and has all properties of non-steroidal anti-inflammatory drug (NSAID). The drugs or agents belonging to chemical class of propionic acid derivatives are used mainly in therapeutic intervention for pain, morning stiffness, and joint swelling. Naproxen is classified as a non-selective non-steroidal anti-inflammatory drug (NSAID) as it inhibits both COX-1/COX-2, mainly known for inhibiting platelet aggregation. COX (Cyclooxygenase) is a prostaglandin-endoperoxide synthase (PTGS) enzyme, which plays an important role in inflammation as well as other physiological functions.

The approved naproxen sodium dosing in the U.S. is a single dose of 220-440 mg, with a dosing interval of every 8 to 12 hours (if the symptoms persists), while the maximum daily dose limit is 600 mg. Naproxen is available in many generic versions and is being marketed in the U.S. as a prescription and over-the-counter (OTC) drug by Genetech (member of Roche group) and Bayer AG, respectively. Naprosyn and Anaprox are prescription brands marketed by Roche. Aleve and Midol Extended Relief are brands marketed by Bayer AG as non-prescription drugs for over-the-counter (OTC) use in over 50 countries in Asia, Africa, and the Caribbean. The first approval outside the U.S. was in 1981 and in most countries the approved non-prescription drug is for temporary pain relief and for fever reduction. In British Colombia, naproxen received approved as over-the-counter (OTC) drug later in January 2010. The global naproxen product labels are generally same as that in the U.S. and with a daily dosing limit of 550 mg or 660 mg in adults and children (12 years and older).

The major driver of the naproxen market is its availability as non-prescription drug and well established profiling of its benefits and risks. Fast track development of new pharmaceutical industries drives the naproxen market. Increase in geriatric population and concomitant rise in arthritis cases also propel the naproxen market. Naproxen is not only consumed in case of arthritis, but also for muscle strain relief, back pain, knee pain, and other myriad of painful cases. This boosts the growth of the naproxen market. Increased risk of cardiovascular events such heart attack and stroke, abdominal bleeding or ulcers, and allergic reactions, especially in case of older population act as restraints of the market.

Fill the form for an exclusive sample of this report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=19571

Naproxen is advised not to be consumed in late pregnancy (during third trimester) as it could lead to premature closing of ductus arteriosus. Hence, accidental consumption of naproxen or any other non-steroidal anti-inflammatory drug (NSAID) during late pregnancy requires baby to be delivered early. Another restraint of the naproxen market is availability of other drugs that have low risk of abdominal ulcers or allergic reactions as compared to naproxen. Therefore, competition in the market from other improved drugs used in pain reduction for arthritis such as steroids and other non-steroidal anti-inflammatory drugs (NSAID) are likely to hamper the naproxen market.

The naproxen market has been segmented based on disease indication, formulation, distribution channel, and region. In terms of disease indication, the market has been segmented into osteoarthritis (OA), rheumatoid arthritis (RA), ankylosing spondylitis, juvenile arthritis, bursitis, menstrual cramps, gout, and tendonitis. Based on formulation, the naproxen market has been segmented into oral tablets and liquid suspension. In terms of distribution channel, the market has been classified into hospital pharmacies, retail pharmacies, drug stores, and e-commerce. Based on region, the naproxen market has been segmented into Asia Pacific (APAC), Europe, Middle East & Africa (MEA), North America (NA), and Latin America (LA).

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

Transparency Market Research (TMR) is a U.S.-based provider of syndicated research, customized research, and consulting services. TMR’s global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

Contact us:
Transparency Market Research
90 State Street,
Suite 700,
Albany
NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Naproxen Market: Latest Innovations, Drivers, Restraints, Challenges and Forecast 2016 - 2024 here

News-ID: 657793 • Views:

More Releases from TMR - Research Reports

Visualization and 3D Rendering Software Market: On-Premise Deployment Presently …
The global market for visualization and 3D rendering features a largely consolidated vendor landscape, with the leading three vendors accounting for a nearly 80% of the overall revenue generated in the market in 2016, observes Transparency Market Research in a recent report. These three vendors, namely Autodesk Inc., Dassault Systems, and NVIDIA Corporation, have strengthened their positions in the market with the help of cost competitive pricing, continuous introduction of
Digital Door Lock Systems Market: Enhanced Security Requirements to Propel the D …
According to a new market report published by Transparency Market Research titled “Digital Door Lock Systems Market–Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018–2026,” the global digital door lock systems market was valued at US$ 1,059.5 Mn in 2017 and is expected to expand at a CAGR of 30.25% from 2018 to 2026, reaching US$ 14,877.6 Mn by the end of the forecast period. digital door lock systems market
Transportation Management System Market: Advance Technologies in All the Sectors …
A transportation management system (TMS) refers to a subset of supply chain management and is centered mostly on logistics and transportation. The augmented use of cloud computing technologies for managing supply chain activities is one of the significant and major trends that have been prevailing in the world market for transportation management systems. Cloud-based deployments, in general, need less configuration and customization. These two factors are triggering down the cost
Energy Recovery Ventilators Market: Rising Awareness of Importance of Indoor Air …
Characterized by the presence of a handful of dominant players, namely United Technologies Corp., LG Electronics, Daikin Industries Ltd., Fujitsu Ltd., and Munters Corp., the global energy recovery ventilators market features intense competition, reveals Transparency Market Research (TMR) in a new report. Going forward, the rising number of players seeking entry will further intensify competition in the market. Expansion of product portfolio which has been the focus of established companies to

All 5 Releases


More Releases for Naproxen

Global Naproxen Market to Witness a Pronounce Growth During 2025
Market Research Report Store offers a latest published report on Naproxen Market Analysis and Forecast 2019-2025 delivering key insights and providing a competitive advantage to clients through a detailed report. This report focuses on the key global Naproxen players, to define, describe and analyze the value, market share, market competition landscape, SWOT analysis and development plans in next few years. To analyze the Naproxen with respect to individual growth trends, future prospects,
Global Naproxen Market Research Report
This report studies the global Naproxen market status and forecast, categorizes the global Naproxen market size (value & volume) by manufacturers, type, application, and region. This report focuses on the top manufacturers in North America, Europe, Japan, China, and other regions (India, Southeast Asia). The major manufacturers covered in this report Teva Kirsch Pharma GmbH Aurobindo Divis Laboratories Taj Pharmaceuticals Limited Tianxin Pharmaceutical Charioteer Pharmaceutical Nhwa Pharmaceutical Huazhong Pharma Geographically,
Naproxen Market - Global Industry Analysis, Size, Share, Growth 2024.
Naproxen is a non-steroidal anti-inflammatory drug (NSAID) commonly used as a prescription drug as well as over-the-counter (OTC). It is generally used in low to moderate pain management and sometimes used for fever reduction. Naproxen was approved in 1976 in the U.S., and was developed originally by Syntex, then acquired by Roche and approved in the U.S. under the brand name Aleve (naproxen sodium) in 1994 for over-the-counter (OTC) use.
Naproxen Market Growth Analysis & Projections Forecast to 2024
Naproxen is a non-steroidal anti-inflammatory drug (NSAID) commonly used as a prescription drug as well as over-the-counter (OTC). It is generally used in low to moderate pain management and sometimes used for fever reduction. Naproxen was approved in 1976 in the U.S., and was developed originally by Syntex, then acquired by Roche and approved in the U.S. under the brand name Aleve (naproxen sodium) in 1994 for over-the-counter (OTC) use.
Naproxen Market Professional Survey Report 2024 Emerging Opportunities
Naproxen is a non-steroidal anti-inflammatory drug (NSAID) commonly used as a prescription drug as well as over-the-counter (OTC). It is generally used in low to moderate pain management and sometimes used for fever reduction. Naproxen was approved in 1976 in the U.S., and was developed originally by Syntex, then acquired by Roche and approved in the U.S. under the brand name Aleve (naproxen sodium) in 1994 for over-the-counter (OTC) use.
Naproxen Market Expected to Be Biggest Emerging Market by 2024
Naproxen is a non-steroidal anti-inflammatory drug (NSAID) commonly used as a prescription drug as well as over-the-counter (OTC). It is generally used in low to moderate pain management and sometimes used for fever reduction. Naproxen was approved in 1976 in the U.S., and was developed originally by Syntex, then acquired by Roche and approved in the U.S. under the brand name Aleve (naproxen sodium) in 1994 for over-the-counter (OTC) use.